Moderna’s Combined Vaccine Gains EU Nod Amid Growing Scrutiny in the U.S.

The European Medicines Agency (EMA) has recommended marketing authorization for Moderna's mCombriax, the world's first combined mRNA vaccine for COVID-19 and seasonal influenza. The recommendation targets adults aged 50 and older, aiming to streamline vaccination schedules for vulnerable populations. However, this regulatory milestone in Europe comes as Moderna faces increased scrutiny in the United States, creating a dual narrative for the biotech giant. While the company seeks international approvals to bolster its post-pandemic revenue, domestic pressure remains a significant focal point for investors. Analysts suggest that while the EU progress is a positive catalyst for MRNA stock, the regulatory environment in the U.S. continues to be a key risk factor. A final decision from the European Commission is expected shortly, which would allow for a commercial rollout across the EU.